Brean Capital analyst Jonathan Aschoff is out today with his second note this week on Repros Therapeutics (NASDAQ:RPRX) maintaining a Buy rating, with a $41 price target, following the company’s third-quarter results.
Aschoff noted, “Repros ended 3Q14 with about $53 million in cash, far more than is needed to file the Androxal NDA. Repros reported interest income for 3Q14 of $2k and EPS of $(0.32).”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 12.7% and a 62.0% success rate. Aschoff has a -1.0% average return when recommending RPRX, and is ranked #173 out of 3367 analysts.
